Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Lisa Bright

Child & Adolescent Psychiatry Juneau, WI Medical Doctor

NPI 1093949760 CMS profile 1332078

199 County Road Df Fl 3, Juneau, WI 53039

Open in the dashboard

General payments

$3,482

224 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Bright of Juneau, WI is reported in the CMS Open Payments database as having received $3,482 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,522 95
2024 General $1,147 72
2023 General $750 54
2022 General $63 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Bright
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Lisa Bright were reported at $1,522. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Lisa Bright Child & Adolescent Psychiatry median Middle half National median
2019 $0 $129 $42–$419 $163
2020 $0 $81 $28–$226 $114
2021 $0 $115 $31–$326 $132
2022 $63 $124 $40–$382 $149
2023 $750 $130 $45–$420 $160
2024 $1,147 $141 $42–$490 $164
2025 $1,522 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Supernus Pharmaceuticals, Inc. $727 60 payments
  2. Lundbeck LLC $653 43 payments
  3. Otsuka America Pharmaceutical, Inc. $338 24 payments
  4. Alkermes, Inc. $300 15 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $231 13 payments
  6. ITI, Inc. $206 10 payments
  7. AbbVie, Inc. $172 11 payments
  8. Corium, Inc. $143 9 payments
  9. E.R. Squibb & Sons, L.L.C. $141 7 payments
  10. Teva Pharmaceuticals USA, Inc. $130 7 payments
  11. Other $441 25 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,482 224 payments
Products named General payments · program years 2022–2025
  1. REXULTI Psychiatry $653 43 payments
  2. Qelbree Viloxazine Hydrochloride $544 45 payments
  3. REXULTI Psychiatry $278 19 payments
  4. LYBALVI $276 14 payments
  5. TRINTELLIX $231 13 payments
  6. ARISTADA Cns $205 10 payments
  7. ARISTADA Cns $205 10 payments
  8. ARISTADA Cns $205 10 payments
  9. ARISTADA Cns $205 10 payments
  10. QELBREE Psychology $183 15 payments
  11. Other $1,599 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record